研究发现,WNTinib延迟了小鼠肝细胞瘤的生长,提高了存活率,针对的是CTNNB1突变。 Study finds WNTinib delays hepatoblastoma tumor growth in mice and enhances survival rates, targeting CTNNB1 mutation.

一项研究表明,WNTinib是一种新药物,实际上延缓了肿瘤的生长,并提高了患肝炎的老鼠的存活率,肝癌是影响儿童的肝癌。 A study has revealed that WNTinib, a new drug, effectively delays tumor growth and enhances survival rates in mice with hepatoblastoma, a liver cancer affecting children. 在针对与癌症有关的特定突变(CTNNB1)时,WNTinib在治疗这一疾病的同时尽量减少对健康细胞的损害方面显示出希望。 Targeting a specific mutation (CTNNB1) associated with the cancer, WNTinib shows promise in treating this condition while minimizing damage to healthy cells. 研究人员强调,需要进一步研究,以澄清毒品机制,提高药物对潜在人类使用的安全性。 Researchers emphasize the need for further studies to clarify the drug's mechanisms and improve its safety for potential human use.